Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy
Insmed Inc. (NASDAQ:INSM) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. On January 23, Roth/MKM began coverage of Insmed Inc. (NASDAQ:INSM) with a Buy rating and a $212 price target. The firm pointed to Insmed’s solid position for further upside in 2026, with predictions that the company’s Brinsupri medication will continue to exceed market expectations.
Moreover, the firm assigned a 75% probability of success to the company’s Phase 3 ENCORE trial, with results expected in March or April. A favorable outcome might generate roughly $1.3 billion in frontline Arikayce sales.
Although Roth/MKM views the brensocatib CEDAR trial for hidradenitis suppurativa as risky, the firm believes the recent CRSsNP setback has reset investor expectations ahead of the second-quarter 2026 report, boosting the stock’s risk/reward outlook.
Insmed Inc. (NASDAQ:INSM) is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. The company’s most advanced programs focus on pulmonary and inflammatory conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Probably Not Just Once or Twice! Fed’s Hawkish Tone Returns as Wall Street Prepares for More Rate Hikes
Wall Street is searching for clues in the Federal Reserve's statements to prepare for the possibility of further interest rate hikes this year.
Federal Reserve's Kashkari: Inflation remains too high and is spreading to every corner of the US economy
Minneapolis Federal Reserve President Neel Kashkari stated that the inflation rate remains too high, and inflationary pressures have gone beyond the impact from oil price shocks caused by the Middle East war.
SingularityNET contract exploit forces Fetch.ai to pause AGIX-FET conversions
